Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.